SCHEMBL3538798

SCHEMBL3538798

CC1CCN(c2cc(N3CCN(C)CC3)c(F)cc2N)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 5/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
KMT2A Q03164 1/20 0.46
GPR174 Q9BXC1 2/20 0.45
MAPT P10636 7/20 0.45
HTT P42858 3/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPK1 P28482 2/20 0.45
RECQL P46063 1/20 0.45
PTK2B Q14289 1/20 0.45
LMNA P02545 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 2/20 0.45
NR4A1 P22736 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2312002 0.81 ALDH1A1 (0.59) ALDH1A1L3MBTL1GAAKMT2AMAPT
SCHEMBL25192960 0.80 ALDH1A1 (0.59) ALDH1A1L3MBTL1GAAMEN1USP2
SCHEMBL30336538 0.80 ALDH1A1 (0.59) ALDH1A1L3MBTL1GAAMEN1USP2
SCHEMBL3538794 0.80 ALDH1A1 (0.50) ALDH1A1GAAMEN1KMT2AGPR174
SCHEMBL16514396 0.79 ALDH1A1 (0.57) ALDH1A1L3MBTL1GAAKMT2AMAPT
SCHEMBL22652116 0.78 ALDH1A1 (0.49) ALDH1A1L3MBTL1GAAMAPTHTT
SCHEMBL3542275 0.77 MAPT (0.76) ALDH1A1GAAMEN1KMT2AGPR174
SCHEMBL3538623 0.77 GAA (0.79) ALDH1A1L3MBTL1GAAMEN1USP2
SCHEMBL14217250 0.77 GAA (0.46) ALDH1A1GAAMEN1USP2KMT2A
SCHEMBL30020094 0.76 ALDH1A1 (0.54) ALDH1A1L3MBTL1GAAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP claimed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US claimed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885L3MBTL1 950/4885GAA 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.